Lycopene supplementation in stable asthma

A placebo-controlled, double-blind, randomised control trial using lycopene-rich supplements to reduce neutrophlic airway inflammation in asthma

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12606000286549

Acronym

DAX

Enrollment

139

Registered

2006-07-07

Start date

2006-07-11

Completion date

2009-02-05

Last updated

2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study in asthma examines the ability of lycopene-rich supplements to improve neutrophilic inflammation and disease control, and to reduce exacerbation frequency and severity. It uses a blinded comparison of subjects consuming lycopene-rich supplements versus placebo. It also includes a comparison group of subjects with a high dietary intake of antioxidants.

Interventions

Following a 2 week washout on a low antioxidant diet, subjects receive oral lycopene supplements (45mg/day) for 12 weeks. A comparison group consume a diet high in antioxidants for the duration of the study.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Stable asthma, Non-smokers

Exclusion criteria

Other respiratory disease, Vitamin or mineral use.

Outcome results